查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球疣治疗市场
市场调查报告书
商品编码
1140719

2022-2029 年全球疣治疗市场

Global Warts Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

2021 年疣治疗市场价值 19.1425 亿美元。预计在预测期内（2022-2029 年）将以 4.90% 的复合年增长率增长。

疣是由人乳头瘤病毒 (HPV) 引起的皮肤生长。它可能会持续数年并在治疗后在相同或不同的区域復发。影响復发的因素似乎与患者的全身免疫状态和局部因素有关。 HPV 有 60 多种类型，其中一些容易引起皮肤疣。

这些通常表现为皮肤上的粗糙肿块，具有各种形状和大小。可以在手肘、手指、膝盖、面部、头皮、脚底等部位进行。它通常发生在手背和手指上。足底疣很痛苦，会使行走变得困难。扁平疣可以大量出现在身体的任何部位。生殖器疣是影响人类的最常见的性传播疾病 (STD)。

预计局部治疗可在数週内消除疣，且副作用最小。局部治疗并不总是有效的。因此，液氮冷冻疗法是一种合适的治疗选择，治愈率在 60% 到 90% 之间，復发率在 20% 到 <10% 之间。

如今，病毒性疣、板状疣和足底疣变得越来越普遍，可以使用现代激光设备和冷冻疗法进行治疗。这些可以用二氧化碳激光或射频手术切除。

市场动态

全球疣治疗市场的增长受到诸如疣患病率上升和治疗剂研发增加等因素的推动。

疣和 HPV 感染率上升推动市场增长

疣是一种常见的皮肤病，可能会自发消退。外用鬼臼毒素治疗尖锐湿疣的复发率在 6% 到 100% 之间。根据美国疾病控制和预防中心 (CDC) 的说法，三个月内生殖器疣的复发是典型的。因此，疣復发率的增加导致产品和治疗的利用率增加，从而推动了疣治疗市场。大约 10% 的儿童和青少年总是有疣。此外，据说有22%的孩子在童年时期会感染疣。

疣是由属于人乳头瘤病毒 (HPV) 家族的病毒引起的常见皮肤病感染。 HPV病毒在角蛋白中过度快速增殖，角蛋白是皮肤表面的一种硬蛋白。例如，根据肛门癌基金会的数据，美国每年估计有 1400 万人感染 HPV。根据美国疾病控制和预防中心 (CDC) 的数据，美国每年约有 340,000 至 360,000 名女性和男性感染 HPV 生殖器疣。因此，疣和HPV感染的日益流行正在推动疣治疗市场的增长。

缺乏认识导致的低诊断率阻碍了疣治疗市场的增长

疣治疗市场的全球增长可能会因缺乏对诊断的认识导致报告病例数少而受到阻碍，这反过来又会使治疗选择变得不那么重要。然而，虽然疣的患病率很高，但患者的诊断率却很低。例如，根据 2018 年健康保护报告，与 2014 年相比，在英格兰参加性健康服务的 15-17 岁女孩的尖锐湿疣发病率下降了 92%。

流行病学

疣可以影响任何人，但已知有几个流行病学变量。某些年龄组容易长疣。 9至16岁的风险最大。男性为 14.5 岁，女性为 13 岁。只有性活跃的人有患尖锐湿疣的风险。使用生肉工作的人特别容易患肉瘤。由于尚未在动物组织中发现 HPV，因此屠夫疣被认为是由职业创伤引起的，可能与工作时的寒冷潮湿环境相结合。

在美国 2017 年至 2027 年的流行病学、历史和前瞻性流行病学（不同疣诊断的总数、按性别划分的生殖器疣病例数、按年龄划分的病例数、与 GW 相关的 HPV 类型、疣解剖）目标地点）。

管道分析

在全球范围内，疣的流行率正在上升，促使市场参与者专注于研发并进入战略发展以开发治疗疣的新药。例如

VP-102目前处于II期，用于治疗皮肤科最常见的三种病毒性皮肤病：传染性软疣、普通疣和外生殖器疣。 .

Verrica 打算开发 VP-103，一种第二种候选斑蝥素，用于治疗足底疣，一种人乳头瘤病毒 (HPV) 皮肤感染。

Novan 正在开发 SB206 作为外用抗病毒凝胶，用于治疗外生殖器疣。 SB206处于2期临床试验中。

COVID-19 影响分析

COVID-19 正在影响全球经济，直接影响生产和需求、供应链中断和市场中断，以及对企业和金融市场的财务影响。

儘管大多数国家/地区都放宽了封锁限制，但人们仍然不愿亲自去看医生，因为担心会传播冠状病毒 (COVID-19)。因此，疣治疗市场的公司在 COVID-19 时代拥抱远程医疗，因为个人更喜欢远程医疗服务。在预测期内，对远程医疗技术的需求将急剧上升。远程医疗应用程序正在帮助加快疣护理领域的优质护理过程。

迫切需要减少临床医生和患者之间的社交距离，这推动了疣治疗领域对远程医疗服务的需求。由于美国有大量活跃的 COVID-19 病例，预计远程医疗服务在流行期间将以较大的复合年增长率增长。预计这将在预测期内推动疣治疗市场。

细分分析

全球疣治疗市场分为疣类型、治疗类型和最终用户。

按类型划分，普通疣主导全球疣治疗市场

根据疣的类型，全球疣治疗市场分为普通疣、生殖器疣、扁平疣、足底疣等。普通疣是由人乳头瘤病毒 (HPV) 引起的皮肤病毒感染。病毒迅速使皮肤外层的细胞增殖。它通常可以在手或手指上完成。据说学生容易感染寻常疣，因为他们经常在学校或大学与多人接触。根据许多科学期刊，普通疣是最常见的疣类型之一。

按治疗类型，物理破坏正在迅速增长

按治疗类型，物理中断部分预计将在预测期内以最快的增长率增长。物理破坏，如液氮冷冻疗法，是治疗尖锐湿疣等普通疣的一线治疗方法，治愈率达 50% 至 80%。冷冻疗法（冷冻疗法、液氮疗法）——一种通过在疣下方和周围形成水泡来冷冻疣的方法。冷冻疗法是一种冷冻疣（液氮）的方法，使疣和周围的皮肤自然脱落。

高频是用高频设备或电极切割疣组织或破坏疣。

激光手术通常用于难以治疗的病例。可能需要一种或多种治疗方法或一种以上的治疗方法来解决问题。

由于水杨酸具有成本效益，它可以改善临床结果。

对于疣治疗的需求不断增长，这种治疗在治疗后不会留下疤痕并提供针对 HPV 的终生免疫力。因此，疣治疗市场的公司越来越关注冷冻疗法、组织角质溶解和免疫疗法，以改善患者的治疗效果。组织角质松解含有水杨酸，是疣药物的一种流行的非处方 (OTC) 选择。这很明显，因为化学破坏治疗选项水杨酸预计在预测期内将在疣治疗市场实现指数级收入增长。

区域分析

按地区划分，全球疣治疗市场分为北美、欧洲、亚太地区、拉丁美洲、中东和非洲。

北美有望主导全球疣治疗市场

到 2021 年，北美将占据全球疣治疗市场的最大市场份额。预计这一趋势将在预测期内持续。据推测，该地区对不同治疗方案的认识和新产品的推出将促进北美疣治疗市场的增长。普通疣的患病率为 2200 万男性和女性，每年诊断出的比例超过 8%。

远程医疗的上升趋势正在导緻美国疣治疗市场发生重大转变。例如，2019 年 12 月，总部位于加州的虚拟护理提供商 GenieMD 推出了一款名为 iVisit 的远程医疗应用程序，以帮助将生殖器疣患者与合格的医生联繫起来进行虚拟就诊。此类产品创新正在推动疣治疗市场的增长。

竞争格局

疣治疗市场的主要参与者正在加紧研发工作，为未感染 HPV 的患者开发改进的疫苗配方。製造商正在提高生产能力，以开发有助于有效治疗生殖器疣的处方药膏和凝胶。

主要参与者正在采取多种增长策略，包括产品发布、收购和合作伙伴关係，为全球疣治疗市场的增长做出了贡献。

贝瑞卡製药

概述

Verrica Pharmaceuticals 成立于 2013 年，总部位于美国。 Verrica Pharmaceuticals, Inc. 是一家皮肤病治疗公司，为需要医疗干预的皮肤病开发药物。我们专注于皮肤病疗法的开发和商业化。该公司的 VP-102目前正在进行临床试验，用于治疗普通和外生殖器疣。

管道产品。

VP-102目前处于II期临床试验中，用于治疗传染性软疣、普通疣和外生殖器疣，这是医学皮肤科最常见的病毒性皮肤病。正在进行中。

Verrica 计划开发 VP-103，这是第二种候选斑蝥素药物装置，用于治疗足底疣，一种人乳头瘤病毒 (HPV) 皮肤感染的足底。

主要发展。

2021 年 3 月，Torii 获得了 Verica 的传染性软疣和寻常疣治疗候选药物在日本的独家开发和商业许可。根据该许可协议，Torii 支付了 1200 万美元的预付款。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按疣类型划分的市场细分
  • 按治疗类型划分的市场细分
  • 最终用户的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 疣的发病率增加
    • 限制因素
      • 严格的监管审批
    • 机会
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 管道分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按疣类型

  • 常见的疣
  • 扁平疣（扁平疣）
  • 跖疣（跖疣）
  • 尖锐湿疣（尖锐湿疣）
  • 其他（甲週疣、丝状疣、马赛克疣等）

第 8 章按治疗类型

  • 物理破坏
    • 冷冻疗法（冷冻）
    • 手术切除
    • 激光治疗
    • 其他
  • 药物治疗
    • 化学破坏
      • 博来霉素（病灶内）
      • 斑蝥素 (VP-102)
      • 水杨酸
      • 其他
    • 免疫调节剂
      • 咪奎莫特 5% - 外用
      • 干扰素 - 外用
      • 二硝基氯苯-外用剂
      • 容易出现局部差异
      • 类维生素A - 局部或口服
      • 其他
    • 疫苗
      • 9价人乳头瘤病毒疫苗（Gardasil 9）
      • 宫颈癌
    • 角质层分离剂
      • 鬼臼树脂（podcon-25、podoven-25、鬼臼树脂）
      • 鬼臼 (Condilox)
      • 三氯乙酸外用製剂（三氯）
      • 5-氟尿嘧啶（Fdex、Fluoroplex）
      • 其他
    • 儿茶素（贝勒根）
    • 其他

第 9 章，最终用户

  • 医院
  • 诊所
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • 默克公司
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Dr. Scholl's
  • Mylan N.V.
  • Novan Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc,
  • Teva Pharmaceutical Industries Ltd
  • Verrica Pharmaceuticals
  • Phio Pharmaceuticals Corp.
  • AIM ImmunoTech, Inc.（List Not Exhaustive）

第13章 DataM

简介目录
Product Code: DMPH2825

Market Overview

Warts Therapeutics Market was valued at USD 1914.25 Million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 4.90% during the forecast period (2022-2029).

Warts are skin growth that is caused by the human papillomavirus (HPV). It may persist for years and recurs at the same or different sites, even after treatment. Some factors influencing recurrence appear to be related to the patient's overall immune status and local factors. There are more than 60 types of HPV and some of which tend to cause warts on the skin.

These commonly appear as rough elevations on the skin and are of different shapes and sizes. One can notice them on elbows, fingers, knees, face, scalp and soles of the feet. These generally occur on the backs of the hands and the fingers. Foot wart causes a lot of pain and makes it difficult to walk. Flat warts occur in large numbers in any part of the body. Genital warts are the most common sexually transmitted diseases (STD) affecting people.

Topical treatments could predictably resolve warts in a few weeks with minimal side effects. Topical treatment may not be effective all the time. Hence, cryotherapy with liquid nitrogen is a suitable option for treatment, where the cure rate is 60% to 90% with less than 20% to 10% recurrence rate.

Viral, flat & plantar warts are widespread can be treated nowadays with the latest lasers equipment & cryotherapy. These can be surgically removed by co2 lasers & radiofrequency.

Market Dynamics

The global warts therapeutics market growth is driven by factors such as the rising prevalence of warts and increasing research & development for treatment drugs.

Rising Prevalence of Warts & HPV Infections is Driving the Market Growth

Warts are a common skin disorder that may regress spontaneously. The recurrence rate for genital warts treated with topical podophyllotoxin treatments is 6% to 100%. A to the Centers for Disease Control and Prevention (CDC), the recurrence of anogenital warts within three months is typical. Thus, an increase in the recurrence rate of warts leads to an increase in the utilization of products and treatment and this drive the market for warts therapeutics. About 10% of children and adolescents have warts at any one time. As many as 22% of children will contract warts during childhood.

Wart is a common dermatological infectious disorder caused by a virus that belongs to the Human Papilloma Virus (HPV) family. HPV viruses cause excessive and rapid growth of keratin, a hard protein on the top layer of the skin. For instance, as per the Anal Cancer Foundation, an estimated 14 million people are infected with HPV in the U.S. every year. According to the Centers for Disease Control and Prevention (CDC), in the U.S., around 340,000 to 360,000 women and men are affected annually by genital warts caused by HPV. Hence, an increase in the prevalence of warts & HPV infections drives the warts therapeutics market growth.

Low Diagnostic Rate Owing to Lack of Awareness is Hampering the Growth of the Warts Therapeutics Market

The global warts therapeutics market growth is likely to be hampered by the lack of awareness of the diagnosis leading to fewer reported cases and subsequently, leads to less significance for treatment options. However, the prevalence of warts is higher, but the diagnosis rate is low in patients. For instance, as per the Health Protection Report in 2018, the rate of genital warts diagnosis among girls aged 15 to 17 years in England, attending sexual health services decreased by 92% as compared to that in 2014.

Epidemiology

While warts can affect anyone, a few epidemiological variables are known. Certain age groups are more prone to warts. Those ages 9 to 16 years are at the highest risk. The peak age is 14.5 years for males and 13 years for females. Only those who are sexually active are at risk of genital warts. People who work with raw meat are at particularly high risk of butcher's warts. Since HPV has not been found in the tissues of the animals, butcher's warts are thought to be caused by occupational trauma, perhaps combined with the cold and moist conditions under which the job is performed.

The epidemiology will provide historical and forecasted epidemiology (Total Diagnosed Incidence of different warts, Gender-specific Cases, Age-specific Cases of Genital Warts, HPV type associated with GWs and Anatomical Location of Warts) in the United States from 2017-2027.

Pipeline Analysis

Globally, the prevalence of warts is rising, which encourages the market players to enter into strategic development, focusing on research and development to develop new drugs for warts treatment. For instance,

VP-102 currently in Phase II is for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

Verrica intends to develop VP-103, a second cantharidin-based drug-device product candidate for the treatment of plantar warts, a skin infection on the bottom of the foot caused by the human papillomavirus (HPV)

Novan, Inc. is in the development of SB206 as a topical antiviral gel for the treatment of external genital warts. SB206 is in clinical trial phase 2.

COVID-19 Impact Analysis

The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets.

Lockdown regulations have been relaxed in most countries, but people are reluctant to visit doctors in person, due to the fear of spreading coronavirus (COVID-19). Thus, companies in the warts therapeutics market are adopting telemedicine as individuals prefer remote healthcare services amidst the COVID-19 era. The demand for telehealth technology will rise dramatically during the forecast period. Telemedicine apps are helping to expedite the process of quality medical care in the sphere of warts therapeutics.

The emergency need for social distancing among clinicians and patients has catalyzed the demand for telemedicine services in the domain of warts therapeutics. Due to the high prevalence of active COVID-19 cases in the United States, telemedicine services are expected to grow at a significant CAGR during the pandemic. This is expected to drive the warts therapeutics market during the forecast period.

Segment Analysis

The global warts therapeutics market is segmented into wart type, treatment type, and end-user.

By Type, Common Warts Dominate the Global Warts Therapeutics Market

Based on warts type, the global warts therapeutics market has been classified into common warts, genital warts, flat warts, plantar warts, and others. The common wart is a cutaneous viral infection caused by human papillomavirus (HPV). This virus causes the rapid growth of cells on the outer layer of your skin. It usually grows on your hands or fingers. Students are more prone to acquiring common warts, owing to increased chances of contact with multiple individuals in schools and colleges. According to numerous published journals, among different warts, common warts are a highly common type of warts.

Based on Treatment Type, Physical Destruction is the Fastest Growing Segment

By treatment type, the physical destruction segment is expected to grow at the fastest growth rate over the forecast period. Physical destruction, such as cryotherapy (freezing) with liquid nitrogen, represents the first line of therapy treatment for warts such as genital warts, common warts which provide cure rates of 50% to 80%. The Freezing (Cryotherapy, or Liquid Nitrogen Therapy)-Freezing works by causing a blister to form under and around your wart. Cryosurgery involves freezing the wart (liquid nitrogen), after which the wart and the surrounding skin fall off by themselves.

Radiofrequency involves cutting away the wart tissue or destroying it by radiofrequency device or electrodesiccation.

Laser Surgery is usually reserved for tough-to-treat cases. More than one treatment or more than one approach to treatment may be necessary to manage the problem.

Salicylic Acid Improves the Clinical Outcomes Owing to Cost-Efficiency

There is a rising demand for wart treatment that offers no scarring post-treatment and provides a lifetime of immunity against HPV. Thus, companies in the warts therapeutics market are increasing their focus on cryotherapy, tissue keratolysis, and immunotherapy to increase patient outcomes. Tissue keratolysis involves salicylic acid and is popular in over-the-counter (OTC) options for warts therapeutics. This is evident since salicylic acid, is a chemical destruction treatment option, is expected to register exponential revenue growth in the warts therapeutics market during the forecast period.

Geographical Analysis

In terms of region, the global warts therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is Expected to Dominate the Global Warts Therapeutics Market

North America accounted for the largest market share of the global warts therapeutics market in 2021. This trend is expected to continue during the forecast period. The growing awareness towards different treatment options and the launch of new products in this region are estimated to boost the warts therapeutics market growth in North America. The prevalence of common warts is 22 million among men and women, and more than 8% are diagnosed annually.

The growing trend of telemedicine is making a significant change in the warts therapeutics market in the United States. For instance, in December 2019, GenieMD, a California-based virtual care delivery company, launched a telemedicine app called iVisit, which helps to connect genital warts patients with the best physicians through a virtual visit. Such product innovations are boosting the growth of the warts therapeutics market.

Competitive Landscape:

Some of the major players in the schistosomiasis treatment market include Merck & Co., Inc., Dr Scholl's, Mylan N.V., Novan Inc., Pfizer, Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Verrica Pharmaceuticals, Phio Pharmaceuticals Corp., AIM ImmunoTech, Inc., among others. The major players in the market of warts therapeutics are increasing their R&D to develop improved formulations of vaccines for patients who have not been previously vaccinated against HPV. Manufacturers are increasing their production capabilities to develop prescription creams and gels that help to effectively treat genital warts.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the warts therapeutics market globally.

Verrica Pharmaceuticals

Overview:

Verrica Pharmaceuticals, founded in 2013 and is headquartered in the United States. Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. It is specialized in the development and commercialization of dermatological treatments. Currently, the company's VP-102 is in the clinical trial phase for common and external genital warts indication.

Pipeline Products:

VP-102 currently in Phase II is for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

Verrica intends to develop VP-103, a second cantharidin-based drug-device product candidate for the treatment of plantar warts, a skin infection on the bottom of the foot caused by the human papillomavirus (HPV)

Key Developments:

In March 2021, Torii acquired the exclusive license to develop and commercialize Verrica's product candidates for the treatment of molluscum contagiosum and common warts in Japan. Under the license agreement, Torii made up-front payments of $12.0 million.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Wart Type
  • 3.2. Market Snippet by Treatment Type
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising incidence of Wart
      • 4.1.1.2. XX
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent regulatory approvals
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Pipeline Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Wart Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type Segment
    • 7.1.2. Market Attractiveness Index, By Wart Type Segment
  • 7.2. Common wart (verruca vulgaris)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Flat wart, or plane wart (verruca plana)
  • 7.4. Plantar wart, or verruca (verruca plantaris)
  • 7.5. Genital wart (condyloma acuminatum)
  • 7.6. Others( Periungual wart, Filiform wart, Mosaic warts)

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Physical Destruction*
    • 8.2.1.
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.2.2. Cryotherapy (Freezing)
    • 8.2.3. Surgical Removal
    • 8.2.4. Laser Treatment
    • 8.2.5. Others
  • 8.3. Medication
    • 8.3.1. Chemical Destruction
      • 8.3.1.1. Bleomycin intralesional
      • 8.3.1.2. Cantharidin (VP-102)
      • 8.3.1.3. Salicylic Acid
      • 8.3.1.4. Others
    • 8.3.2. Immunomodulatory agent
      • 8.3.2.1. Imiquimod 5% - topical
      • 8.3.2.2. Interferon - intralesional
      • 8.3.2.3. Dinitrochlorobenzene - topical
      • 8.3.2.4. Diphencyprone topical
      • 8.3.2.5. Retinoids - topical or oral
      • 8.3.2.6. Others
    • 8.3.3. Vaccines
      • 8.3.3.1. Human papillomavirus vaccine, nonavalent (Gardasil 9)
      • 8.3.3.2. Cervarix
    • 8.3.4. Keratolytics
      • 8.3.4.1. Podophyllum resin (Podocon-25, Podo-Ben-25, Podofin)
      • 8.3.4.2. Podofilox (Condylox)
      • 8.3.4.3. Trichloroacetic acid topical (Tri-Chlor)
      • 8.3.4.4. 5-Fluorouracil (Efudex, Fluoroplex)
      • 8.3.4.5. Others
    • 8.3.5. Kunecatechins (Veregen)
    • 8.3.6. Other

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User Segment
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3. Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Site
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.7.1. Brazil
      • 10.6.7.2. Argentina
      • 10.6.7.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Wart Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co., Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Dr. Scholl's
  • 12.3. Mylan N.V.
  • 12.4. Novan Inc.
  • 12.5. Pfizer, Inc.
  • 12.6. GlaxoSmithKline plc,
  • 12.7. Teva Pharmaceutical Industries Ltd
  • 12.8. Verrica Pharmaceuticals
  • 12.9. Phio Pharmaceuticals Corp.
  • 12.10. AIM ImmunoTech, Inc. (List Not Exhaustive)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us